Vivo Bio Tech Ltd Announces Unaudited Financial Results for First Quarter Ended June 30, 2026
Vivo Bio Tech Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, following approval by its Board of Directors. The results reflect the company's operations across its segments, which are primarily focused in Bio Technology.The company also released the unaudited results, along with a Limited Review Report issued by Statutory Auditors M/s. P. Murali & Co., Chartered Accountants.
Consolidated Financial Results Overview
The consolidated financial performance reflects the results of all subsidiaries, including Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited, and Vivobio Consulting Services Private Limited (formerly Donakanti Consulting Services Private Limited).Key figures from the Consolidated Financial Results are presented below:
| PARTICULARS | 30.06.2026 Un-Audited (Rs. in Lacs) | 31.03.2026 Audited (Rs. in Lacs) | 30.06.2025 Un-Audited (Rs. in Lacs) | 31.03.2026 Audited (Rs. in Lacs) |
|---|---|---|---|---|
| Revenue from operations | 1,427.97 | 1,420.11 | 1,251.16 | 5,333.47 |
| Other Income | 5.54 | 3.04 | 13.78 | 44.08 |
| Total Income | 1,433.51 | 1,423.16 | 1,264.94 | 5,377.55 |
| Expenses (Total) | 1,399.65 | 1,337.60 | 1,116.95 | 4,836.12 |
| Profit Before Tax | 33.86 | 85.56 | 147.99 | 541.44 |
| Total Tax Expense | 15.10 | 541.38 | 14.29 | 651.88 |
| Net Profit After Tax | 18.76 | -516.27 | 133.71 | -170.88 |
The consolidated results show that the company’s Paid Up Share Capital stood at 2,219.06 lakh Units for the quarter ended June 30, 2026. Earnings per share (EPS) were reported as follows:
| Metric | Q1 Ended June 30, 2026 | Q4 Ended March 31, 2026 | Q1 Ended June 30, 2025 |
|---|---|---|---|
| Basic Earnings per equity share | 0.08 | -2.52 | 0.74 |
| Diluted Earnings per equity share | 0.08 | 252 | 0.74 |
Standalone Financial Results Details
The Unaudited Standalone Financial Results for the quarter ended June 30, 2026, reflect the performance of the parent company.A summary of the standalone figures is provided in the table below:
| PARTICULARS | 30.06.2026 Un-Audited (Rs. in Lacs) | 31.03.2026 Audited (Rs. in Lacs) | 30.06.2025 Un-Audited (Rs. in Lacs) | 31.03.2026 Audited (Rs. in Lacs) |
|---|---|---|---|---|
| Revenue from operations | 1,413.94 | 1,376.72 | 1,241.86 | 5,256.84 |
| Other Income | 5.54 | 3.04 | 13.78 | 44.08 |
| Total Income | 1,419.48 | 1,379.77 | 1,255.64 | 5,300.93 |
| Expenses (Total) | 1,385.95 | 1,321.63 | 1,104.04 | 4,782.22 |
| Profit Before Tax & Exceptional Items | 33.53 | 58.14 | 151.61 | 518.71 |
| Net Profit After Tax | 18.43 | -543.69 | 137.32 | -193.61 |
The standalone financial data also includes the following key metrics:
| Metric | Q1 Ended June 30, 2026 | Q4 Ended March 31, 2026 | Q1 Ended June 30, 2025 |
|---|---|---|---|
| Basic Earnings per equity share | 0.08 | -2.65 | 0.76 |
| Diluted Earnings per equity share | 0.08 | -2.65 | 0.76 |
The results have been reviewed by the Audit Committee and approved by the Board of Directors, with the figures for March 31, 2026, representing balancing figures between audited full financial year statements and published year-to-date figures subject to Limited Review by the Statutory Auditor.
Stock Price Movement
Vivo Bio Tech Ltd settled at ₹25.19 on Monday after its shares surged by 6.87%.The stock traded within a range throughout the day, moving between a low of ₹23.70 and an intraday high of ₹25.67.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: